Nelfinavir and lamivudine pharmacokinetics during the first two weeks of life

Pediatric Infectious Disease Journal

Volumn 30, Issue 9, 2011, Pages 769-772

  Mirochnick, Mark ^a   Nielsen Saines, Karin ^b   Pilotto, Jose Henrique ^c   Pinto, Jorge ^d   Veloso, Valdilea Gonçalves ^e   Rossi, Steven ^f   Moye, Jack ^g   Bryson, Yvonne ^b   Mofenson, Lynne ^g   Camarca, Margaret ^h   Watts, D Heather ^g  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOSPITAL GERAL DE FORTALEZA   (Brazil)

^d FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^e Funda??o Oswaldo Cruz   (Brazil)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h WESTAT   (United States)

Author keywords

lamivudine; Nelfinavir; newborns; pharmacokinetics

Indexed keywords

LAMIVUDINE; NELFINAVIR;

AREA UNDER THE CURVE; ARTICLE; BRAZIL; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NEWBORN; NEWBORN INTENSIVE CARE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS TRANSMISSION;

EID: 80051917317     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3182242950     Document Type: Article

References (16)

1. Mirochnick M, Stek A, Acevedo M, et al. Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. J Acquir Immune Defic Syndr. 2005;39:189-194. (Pubitemid 40741117)
2. Rongkavilit C, van Heeswijk RP, Limpongsanurak S, et al. Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates. J Acquir Immune Defic Syndr. 2002;29:455-463. (Pubitemid 34456336)
3. WHO Paediatric Antiretroviral Working Group. Preferred antiretroviral medicines for treating and preventing HIV infection in younger children. 2007; http://www.who.int/hiv/pub/paediatric/ARV-WG-meeting-report-may2008.pdf. Accessed June 12, 2008.
4. Chadwick EG, Capparelli EV, Yogev R, et al. Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS. 2008;22:249-255.
5. FDA. Safety alert-Kaletra (lopinavir/ritonavir): Label Change-Serious Health Problems in Premature Babies. Available at: http://www.fda.gov/Safety/ MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm246167.htm. Accessed March 8, 2011.
6. Capparelli EV, Sullivan JL, Mofenson L, et al. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr Infect Dis J. 2001;20:746-751. (Pubitemid 32758015)
7. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis. 1999;28:1109-1118. (Pubitemid 29203548)
8. Litalien C, Faye A, Compagnucci A, et al. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 2003;22:48-55. (Pubitemid 36091778)
9. Payen S, Faye A, Compagnucci A, et al. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2005;49:525-535. (Pubitemid 40175657)
10. Hirt D, Urien S, Jullien V, et al. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. Antimicrob Agents Chemother. 2006;50:910-916. (Pubitemid 43327794)
11. Moodley D, Pillay K, Naidoo K, et al. Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours. J Clinic Pharmacol. 2001;41:732-741. (Pubitemid 32612436)
12. Tremoulet AH, Capparelli EV, Patel P, et al. Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and-infected infants. Antimicrob Agents Chemother. 2007;51:4297-4302. (Pubitemid 350209880)
13. Heald AE, Hsyu PH, Yuen GJ, et al. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996;40:1514-1519. (Pubitemid 26169059)
14. Coates JA, Cammack N, Jenkinson HJ, et al. (-)-2́-deoxy-3́- thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother. 1992;36: 733-739.
15. Nielsen-Saines K, Watts H, Gonçalves Veloso V, et al. Phase III Randomized Trial of the Safety and Efficacy of 3 Neonatal ARV Regimens for Prevention of Intrapartum HIV-1 Transmission: NICHD HPTN 040/PACTG 1043. Paper presented at: 18th Conference on Retroviruses and Opportunistic Infections; March 2, 2011; Boston, MA. Abstract 124LB.
16. Mirochnick M, Nielsen-Saines K, Pilotto JH, et al. Nevirapine concentrations in newborns receiving an extended prophylactic regimen. J Acquir Immune Defic Syndr. 2008;47:334-337. (Pubitemid 351619419)